ECT2, firmly established as an oncogene, exhibits consistent overexpression across ovarian, cervical, and endometrial cancers, a phenomenon intricately intertwined with tumor initiation, malignant progression, and adverse patient prognosis. This evidence concerns the gene ECT2 and endometrial cancer.